HUNTINGTON BEACH, Calif., Aug. 8, 2005 (PRIMEZONE) -- WayPoint Biomedical Corporation (Pink Sheets:WYPB) Executives recently attended the annual IFCC/AACC Clinical Lab Exposition in Orlando, Florida. Although the 2005 expo statistics are not yet available, the 2004 meeting in Los Angeles registered over 19,000 participants from more than 100 countries, with over 600 different corporate exhibitors. This year's conference is expected to post similar participant and exhibitor attendance statistics.
WayPoint President & COO, Bret Hendzel commented, "The IFCC/AACC Conference offered an exceptional opportunity for WayPoint to meet with a multitude of current and potential customers and vendors in one location." Mr. Hendzel added, "With our new range of urine-based diagnostic rapid tests about to be introduced into the clinical sector, the exhibition allowed WayPoint to begin face-to-face negotiations with several of the key market leaders who hold a significant share of the multi-million dollar urine chemistry market segment. The tradeshow also allowed WayPoint to acquire up-to-date industry intelligence on new products, trends and innovations."
In addition to holding numerous meetings with various international and domestic customers, strategic planning sessions were also held with key vendors and development partners, such as Derby, U.K.-based SureScreen Diagnostics.
A majority of the major clinical diagnostic industry leaders exhibited at the meeting, including: Abbott Diagnostics (ABT), Abaxis (ABAX), Beckman Coulter (BEC), Clinical Data (CLDA), Cardinal Health (CAH), Fisher Healthcare (FSH), Gen-Probe (GPRO), Millipore (MIL), Ortho-Clinical Diagnostics (JNJ), Quidel (QDEL), Specialty Labs (SP), and Thermo Electron (TMO).
About WayPoint Biomedical:
WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (Pink Sheets:WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.